New melatonin- N, N -dibenzyl(N -methyl)amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for alzheimers disease

Journal of Medicinal Chemistry

Volumn 57, Issue 9, 2014, Pages 3773-3785

  López Iglesias, Beatriz ^a   Pérez, Concepción ^a   Morales García, José A ^b,c   Alonso Gil, Sandra ^b,c   Pérez Castillo, Ana ^b,c   Romero, Alejandro ^d,e   López, Manuela G ^d   Villarroya, Mercedes ^d   Conde, Santiago ^a   Rodríguez Franco, María Isabel ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUTO TEÓFILO HERNANDO   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[(2 CHLOROBENZYL)(METHYL)AMINO]METHYL] N [2 (5 METHOXY 1H INDOL 3 YL)ETHYL]BENZAMIDE; 4 [[(3 CHLOROBENZYL)(METHYL)AMINO]METHYL] N [2 (5 METHOXY 1H INDOL 3 YL)ETHYL]BENZAMIDE; 4 [[(3 CHLOROBENZYL)(METHYL)AMINO]METHYL] N [2 (6 METHOXY 1H INDOL 3 YL)ETHYL]BENZAMIDE; 4 [[BENZYL(METHYL)AMINO]METHYL] N [2 (5 HYDROXY 1H INDOL 3 YL)ETHYL]BENZAMIDE; 4 [[BENZYL(METHYL)AMINO]METHYL] N [2 (5 METHOXY 1H INDOL 3 YL)ETHYL]BENZAMIDE; 4 [[BENZYL(METHYL)AMINO]METHYL] N [2 (6 FLUORO 1H INDOL 3 YL)ETHYL]BENZAMIDE; 4 [[BENZYL(METHYL)AMINO]METHYL] N [2 (6 METHOXY 1H INDOL 3 YL)ETHYL]BENZAMIDE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; MELATONIN; MELATONIN N,N DIBENZYL(N METHYL)AMINE; N [2 (1H INDOL 3 YL)ETHYL] 4 [[(2 CHLOROBENZYL)(METHYL)AMINO]METHYL]BENZAMIDE; N [2 (1H INDOL 3 YL)ETHYL] 4 [[(2 METHOXYBENZYL)(METHYL)AMINO]METHYL]BENZAMIDE; N [2 (1H INDOL 3 YL)ETHYL] 4 [[(3 CHLOROBENZYL)(METHYL)AMINO]METHYL]BENZAMIDE; N [2 (1H INDOL 3 YL)ETHYL] 4 [[(3 METHOXYBENZYL)(METHYL)AMINO]METHYL]BENZAMIDE; N [2 (1H INDOL 3 YL)ETHYL] 4 [[BENZYL(METHYL)AMINO]METHYL]BENZAMIDE; N [2 (5 METHOXY 1H INDOL 3 YL)ETHYL] 4 [[(2 METHOXYBENZYL)(METHYL)AMINO]METHYL]BENZAMIDE; N [2 (5 METHOXY 1H INDOL 3 YL)ETHYL] 4 [[(3 METHOXYBENZYL)(METHYL)AMINO]METHYL]BENZAMIDE; NEUROPROTECTIVE AGENT; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL MATURATION; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CYTOTOXICITY; HUMAN; HUMAN CELL; NERVE CELL; NEURAL STEM CELL; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; RAT;

ALZHEIMER DISEASE; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; CELL LINE; CHOLINESTERASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MELATONIN; NEUROPROTECTIVE AGENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84900336722     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5000613     Document Type: Article

References (60)

1. Sloane, P. D.; Zimmerman, S.; Suchindran, C.; Reed, P.; Wang, L.; Boustani, M.; Sudha, S. The public health impact of Alzheimers disease, 2000-2050: Potential implication of treatment advances Annu. Rev. Public Health 2002, 23, 213-231
2. Querfurth, H. W.; LaFerla, F. M. Alzheimers disease N. Engl. J. Med. 2010, 362, 329-344
3. Bond, M.; Rogers, G.; Peters, J.; Anderson, R.; Hoyle, M.; Miners, A.; Moxham, T.; Davis, S.; Thokala, P.; Wailoo, A.; Jeffreys, M.; Hyde, C. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimers disease (review of technology appraisal no. 111): A systematic review and economic model Health Technol. Assess. 2012, 16, 1-470
4. Wilkinson, D.; Wirth, Y.; Goebel, C. Memantine in patients with moderate to severe Alzheimers disease: Meta-analyses using realistic definitions of response Dementia Geriatr. Cognit. Disord. 2013, 37, 71-85
5. Inestrosa, N. C.; Dinamarca, M. C.; Alvarez, A. Amyloid-cholinesterase interactions. Implications for Alzheimers disease FEBS J. 2008, 275, 625-632
6. Rees, T.; Hammond, P. I.; Soreq, H.; Younkin, S.; Brimijoin, S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex Neurobiol. Aging 2003, 24, 777-787
7. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation Biochemistry 2001, 40, 10447-10457
8. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies Biochem. Pharmacol. 2003, 65, 407-416
9. Viayna, E.; Sabate, R.; Muñoz-Torrero, D. Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates Curr. Top. Med. Chem. 2013, 13, 1820-1842
10. García-Palomero, E.; Muñoz, P.; Usán, P.; García, P.; Delgado, E.; De Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martinez, A. Potent beta-amyloid modulators Neurodegener. Dis. 2008, 5, 153-156
11. Spuch, C.; Antequera, D.; Fernández-Bachiller, M. I.; Rodríguez-Franco, M. I.; Carro, E. A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimers disease Neurotoxic. Res. 2010, 17, 421-431
12. Antequera, D.; Bolos, M.; Spuch, C.; Pascual, C.; Ferrer, I.; Fernández-Bachiller, M. I.; Rodríguez-Franco, M. I.; Carro, E. Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Abeta accumulation and cell death: Involvement in hippocampal neuronal loss in Alzheimers disease Neurobiol. Dis. 2012, 46, 682-691
13. Lorrio, S.; Gómez-Rangel, V.; Negredo, P.; Egea, J.; León, R.; Romero, A.; Dal-Cim, T.; Villarroya, M.; Rodríguez-Franco, M. I.; Conde, S.; Arce, M. P.; Roda, J. M.; García, A. G.; López, M. G. Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia Neuropharmacology 2013, 67, 403-411
14. Ansari, M. A.; Scheff, S. W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex J. Neuropathol. Exp. Neurol. 2010, 69, 155-167
15. Gu, F.; Zhu, M.; Shi, J.; Hu, Y.; Zhao, Z. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice Neurosci. Lett. 2008, 440, 44-48
16. Caldeira, G. L.; Ferreira, I. L.; Rego, A. C. Impaired transcription in Alzheimers disease: Key role in mitochondrial dysfunction and oxidative stress J. Alzheimers Dis. 2013, 34, 115-131
17. Huang, Q.; Aluise, C. D.; Joshi, G.; Sultana, R.; St Clair, D. K.; Markesbery, W. R.; Butterfield, D. A. Potential in vivo amelioration by N-acetyl- l -cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: Toward therapeutic modulation of mild cognitive impairment J. Neurosci. Res. 2010, 88, 2618-2629
18. Altman, J. Are new neurons formed in the brains of adult mammals? Science 1962, 135, 1127-1128
19. Eriksson, P. S.; Perfilieva, E.; Björk-Eriksson, T.; Alborn, A. M.; Nordborg, C.; Peterson, D. A.; Gage, F. H. Neurogenesis in the adult human hippocampus Nat. Med. 1998, 4, 1313-1317
20. Spalding, K. L.; Bergmann, O.; Alkass, K.; Bernard, S.; Salehpour, M.; Huttner, H. B.; Boström, E.; Westerlund, I.; Vial, C.; Buchholz, B. A.; Possnert, G.; Mash, D. C.; Druid, H.; Frisén, J. Dynamics of hippocampal neurogenesis in adult humans Cell 2013, 153, 1219-1227
21. Abdipranoto, A.; Wu, S.; Stayte, S.; Vissel, B. The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development CNS Neurol. Disord.: Drug Targets 2008, 7, 187-210
22. Bubenik, G. A.; Konturek, S. J. Melatonin and aging: Prospects for human treatment J. Physiol. Pharmacol. 2011, 62, 13-19
23. Reiter, R. J.; Manchester, L. C.; Tan, D. X. Neurotoxins: Free radical mechanisms and melatonin protection Curr. Neuropharmacol. 2010, 8, 194-210
24. Reiter, R. J. Oxidative damage in the central nervous system: Protection by melatonin Prog. Neurobiol. 1998, 56, 359-384
25. Pandi-Perumal, S. R.; BaHammam, A. S.; Brown, G. M.; Spence, D. W.; Bharti, V. K.; Kaur, C.; Hardeland, R.; Cardinali, D. P. Melatonin antioxidative defense: Therapeutical implications for aging and neurodegenerative processes Neurotoxic. Res. 2013, 23, 267-300
26. Lin, L.; Huang, Q. X.; Yang, S. S.; Chu, J.; Wang, J. Z.; Tian, Q. Melatonin in Alzheimers disease Int. J. Mol. Sci. 2013, 14, 14575-14593
27. Ramírez-Rodríguez, G.; Klempin, F.; Babu, H.; Benítez-King, G.; Kempermann, G. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice Neuropsychopharmacology 2009, 34, 2180-2191
28. Domínguez-Alonso, A.; Ramírez-Rodríguez, G.; Benítez-King, G. Melatonin increases dendritogenesis in the hilus of hippocampal organotypic cultures J. Pineal Res. 2012, 52, 427-436
29. Liu, J.; Somera-Molina, K. C.; Hudson, R. L.; Dubocovich, M. L. Melatonin potentiates running wheel-induced neurogenesis in the dentate gyrus of adult C3H/HeN mice hippocampus J. Pineal Res. 2013, 54, 222-231
30. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
31. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
32. León, R.; García, A. G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimers disease Med. Res. Rev. 2013, 33, 139-189
33. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimers disease Angew. Chem., Int. Ed. 2007, 46, 3689-3692
34. Capurro, V.; Busquet, P.; Lopes, J. P.; Bertorelli, R.; Tarozzo, G.; Bolognesi, M. L.; Piomelli, D.; Reggiani, A.; Cavalli, A. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimers disease PLoS One 2013, 8, e56870-1-e56870-8
35. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimers disease treatment Curr. Drug Targets 2012, 13, 483-494
36. Viayna, E.; Gómez, T.; Galdeano, C.; Ramírez, L.; Ratia, M.; Badía, A.; Clos, M. V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Camps, P.; Muñoz-Torrero, D. Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates ChemMedChem. 2010, 5, 1855-1870
37. Ratia, M.; Giménez-Llort, L.; Camps, P.; Muñoz-Torrero, D.; Pérez, B.; Clos, M. V.; Badía, A.; Huprine, X. and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimers disease in triple transgenic mice (3xTg-AD) Neurodegener. Dis. 2013, 11, 129-140
38. Fernández-Bachiller, M. I.; Pérez, C.; Monjas, L.; Rademann, J.; Rodríguez-Franco, M. I. New tacrine-4-oxo-4 H -chromene hybrids as multifunctional agents for the treatment of Alzheimers disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties J. Med. Chem. 2012, 55, 1303-1317
39. Fernández-Bachiller, M. I.; Pérez, C.; González- Muñoz, G. C.; Conde, S.; López, M. G.; Villarroya, M.; García, A. G.; Rodríguez-Franco, M. I. Novel tacrine-8- hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimers disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties J. Med. Chem. 2010, 53, 4927-4937
40. Arce, M. P.; Rodríguez-Franco, M. I.; González-Muñoz, G. C.; Pérez, C.; López, B.; Villarroya, M.; López, M. G.; García, A. G.; Conde, S. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimers disease J. Med. Chem. 2009, 52, 7249-7257
41. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 2006, 49, 459-462
42. Fernández-Bachiller, M. I.; Pérez, C.; Campillo, N. E.; Páez, J. A.; González-Muñoz, G. C.; Usán, P.; García-Palomero, E.; López, M. G.; Villarroya, M.; García, A. G.; Martínez, A.; Rodríguez-Franco, M. I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimers disease, with cholinergic, antioxidant, and neuroprotective properties ChemMedChem. 2009, 4, 828-841
43. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl) amino]methyl]phenyl)-6,7-dimethoxy-2 H -2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: A dual function lead for Alzheimers disease therapy J. Med. Chem. 2003, 46, 2279-2282
44. Piazzi, L.; Cavalli, A.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Andrisano, V.; Recanatini, M.; Rampa, A. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2 H -2-chromenone (AP2238) derivatives J. Med. Chem. 2007, 50, 4250-4254
45. Rizzo, S.; Bartolini, M.; Ceccarini, L.; Piazzi, L.; Gobbi, S.; Cavalli, A.; Recanatini, M.; Andrisano, V.; Rampa, A. Targeting Alzheimers disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238 Bioorg. Med. Chem. 2010, 18, 1749-1760
46. Gilman, H.; Bailie, J. C. Relative reactivities of organometallic compounds. XVII. The azo linkage J. Org. Chem. 1937, 2, 84-94
47. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95
48. Brunhofer, G.; Fallarero, A.; Karlsson, D.; Batista-Gonzalez, A.; Shinde, P.; Gopi Mohan, C.; Vuorela, P. Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: The case of chelerythrine Bioorg. Med. Chem. 2012, 20, 6669-6679
49. Di Pietro, O.; Viayna, E.; Vicente-García, E.; Bartolini, M.; Ramón, R.; Juárez-Jiménez, J.; Clos, M. V.; Pérez, B.; Andrisano, V.; Luque, F. J.; Lavilla, R.; Muñoz-Torrero, D. 1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: Synthesis, pharmacological evaluation and mechanistic studies Eur. J. Med. Chem. 2014, 73, 141-152
50. Taylor, P.; Lappi, S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding Biochemistry 1975, 14, 1989-1997
51. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232
52. Dávalos, A.; Gómez-Cordovés, C.; Bartolomé, B. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay J. Agric. Food Chem. 2004, 52, 48-54
53. Sofic, E.; Rimpapa, Z.; Kundurovic, Z.; Sapcanin, A.; Tahirovic, I.; Rustembegovic, A.; Cao, G. Antioxidant capacity of the neurohormone melatonin J. Neural Transm. 2005, 112, 349-358
54. Egea, J.; Rosa, A. O.; Cuadrado, A.; García, A. G.; López, M. G. Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress J. Neurochem. 2007, 102, 1842-1852
55. 2+ oscillations induced by veratridine Eur. J. Pharmacol. 1994, 270, 331-339
56. Ferrón, S. R.; Andreu-Agullo, C.; Mira, H.; Sánchez, P.; Marqués-Torrejón, M. A.; Farinas, I. A combined ex/in vivo assay to detect effects of exogenously added factors in neural stem cells Nat. Protoc. 2007, 2, 849-859
57. Morales-García, J. A.; Luna-Medina, R.; Alfaro-Cervello, C.; Cortes-Canteli, M.; Santos, A.; García-Verdugo, J. M.; Pérez-Castillo, A. Peroxisome proliferator-activated receptor gamma ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo Glia 2011, 59, 293-307
58. Morales-García, J. A.; Luna-Medina, R.; Alonso-Gil, S.; Sanz-Sancristóbal, M.; Palomo, V.; Gil, C.; Santos, A.; Martínez, A.; Pérez-Castillo, A. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo ACS Chem. Neurosci. 2012, 3, 963-971
59. Ou, B.; Hampsch-Woodill, M.; Prior, R. L. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe J. Agric. Food Chem. 2001, 49, 4619-4626
60. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 1986, 89, 271-277